On May 16, 2023 Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, reported that about 30 accepted abstracts of clinical data from multiple trials in relation to TYVYT (sintilimab injection), olverembatinib (BCR-ABL TKI), IBI326 (equecabtagene autoleucel), IBI376 (parsaclisib), IBI110 (anti-LAG-3 monoclonal antibody), IBI939 (anti-TIGIT monoclonal antibody) and IBI351 (KRASG12C inhibitor) will be presented at the upcoming international medical conferences. A brief summary of the selected presentations is as follows (Press release, Innovent Biologics, MAY 16, 2023, View Source [SID1234631788]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING 2023 (Jun 2-6)
Topic: PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM).[1]
Presentation Type: Oral Presentation
Presentation Time：June 5, 2023, 08:00 – 11:00 (GMT-5) Chicago, IL, U.S.
Abstract Number: LBA 6002
Main Researcher: Professor Jun Ma and Professor Liu Xu, Department of Radiation Oncology, Sun Yat-sen University Cancer Center
Topic: Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Updated results from a phase 1b study
Presentation Type: Poster Presentation
Abstract Number: 2576
Main Researchers: Professor Nong Xu and Professor Chenyu Mao, The First Affiliated Hospital, School of Medicine, Zhejiang University.
Topic: Efficacy and safety of IBI110 in combination with sintilimab in first-line of advanced hepatocellular carcinoma: preliminary results from a phase 1b study
Presentation Type: Poster Presentation
Abstract Number: 2577
Main Researcher: Professor Baocai Xing and Professor Ming Liu, Peking University Cancer Hospital & Institute.
Topic: Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: preliminary results from a pooled analysis of two phase 1 studies
Presentation Type: Poster Presentation
Abstract Number: 3586
Main Researcher: Professor Ying Yuan and Professor Kefeng Ding, The Second Affiliated Hospital, Zhejiang University School of Medicine.
Topic: CT103A, a novel fully human BCMA-targeting CAR-T therapy, in patients with relapsed/refractory multiple myeloma: updated long-term follow-up results of phase 1b/2 study (FUMANBA-1)
Presentation Type: Poster Presentation
Abstract Number: 8025
Main Researchers: Professor Chunrui Li, Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science; Professor Lugui Qiu, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College.
Topic: Antitumor activity of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST)
Presentation Type: Poster Presentation
Abstract Number: 11540
Main Researcher: Professor Haibo Qiu, Sun Yat-sen University Cancer Center.
Topic: A study to evaluate the safety, tolerability and efficacy of IBI939 in combination with sintilimab in patients with previously untreated locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC): updated efficacy and safety results
Presentation Type: Online Publication
Abstract Number: e14578
Main Researcher: Professor Ying Cheng and Professor Chunjiao Wu, Jilin Cancer Hospital.
EUROPEAN HEMATOLOGY ASSOCIATION (EHA) (Free EHA Whitepaper) 2023 Hybrid Congress (Jun 8-15)
Topic: CD47/PD-L1 bispecific antibody (IBI322) in anti-PD-1 or PD-L1 treatment-resistant classical Hodgkin lymphoma: a Phase 1 study
Presentation Type: Oral Presentation
Presentation Time: June 11, 2023, 11:30 – 12:45 (CEST) Frankfurt, Germany
Abstract Number: S216
Main Researchers: Professor Ting Niu, West China Hospital of Sichuan University; Professor Huilai Zhang, Tianjin Medical University Cancer Institute & Hospital.
Topic: A phase 2, multicenter, single-arm study of parsaclisib, a PI3kδ inhibitor, in relapsed or refractory follicular lymphoma in China: updated results from the study
Presentation Type: Poster Presentation
Abstract Number: P1099
Main Researcher: Professor Weili Zhao and Professor Zhong Zheng, Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine.
Topic: Safety and efficacy of IBI346, a first-in-class BCMA-targeting modular CAR-T cell therapy, for patients with relapsed/refractory multiple myeloma (RR MM): preliminary results from two Phase 1 studies
Presentation Type: Poster Presentation
Abstract Number: P1406
Main Researcher: Professor Zhengzheng Fu and Professor Depei Wu, The First Affiliated Hospital of Soochow University; Professor Chunrui Li, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.